Pacira BioSciences, Inc. $PCRX Holdings Raised by Impax Asset Management Group plc

Impax Asset Management Group plc lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 27.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600,027 shares of the company’s stock after acquiring an additional 130,000 shares during the period. Impax Asset Management Group plc owned about 1.34% of Pacira BioSciences worth $15,463,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. increased its stake in Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock valued at $50,925,000 after purchasing an additional 565,288 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Pacira BioSciences by 77.2% in the 2nd quarter. American Century Companies Inc. now owns 1,182,513 shares of the company’s stock valued at $28,262,000 after buying an additional 515,090 shares during the period. Geode Capital Management LLC grew its position in shares of Pacira BioSciences by 0.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,143,190 shares of the company’s stock valued at $27,326,000 after buying an additional 5,658 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock worth $27,454,000 after acquiring an additional 367,869 shares during the period. Finally, Bridgeway Capital Management LLC lifted its holdings in Pacira BioSciences by 7.4% in the second quarter. Bridgeway Capital Management LLC now owns 460,273 shares of the company’s stock worth $11,001,000 after acquiring an additional 31,744 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PCRX shares. Wall Street Zen upgraded Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a research note on Friday, January 9th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Pacira BioSciences in a research note on Friday, January 9th. Finally, Barclays began coverage on shares of Pacira BioSciences in a report on Tuesday, December 9th. They set an “equal weight” rating and a $27.00 price target for the company. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pacira BioSciences has an average rating of “Hold” and an average target price of $30.75.

Insider Activity

In other Pacira BioSciences news, SVP Lauren Riker sold 4,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. This trade represents a 7.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan Slonin sold 3,960 shares of Pacira BioSciences stock in a transaction on Monday, November 17th. The shares were sold at an average price of $24.09, for a total value of $95,396.40. Following the transaction, the insider owned 178,367 shares in the company, valued at approximately $4,296,861.03. This trade represents a 2.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 38,336 shares of company stock worth $935,108 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX opened at $21.73 on Thursday. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $27.64. The stock’s fifty day moving average is $23.34 and its 200-day moving average is $23.87. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.78 and a current ratio of 5.26. The firm has a market capitalization of $934.74 million, a price-to-earnings ratio of 48.29 and a beta of 0.24.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.